Custom carbon-14:Layout 1 14/1/10 19:57 Page 60
Radiolabelling
and not least difficulty in acquiring trained radio- Also, isotope groups cannot be moved easily as
chemists. Examples of internal radiolabelling laboratories have specific licences and if centralised
groups closed over recent decades are shown in cause added problems on divestiture.
Table 2.
A complicating factor is that isotope laborato- Conclusion
ries do not always fit comfortably in an organisa- So what of the future? Consolidation continues
tion as they cover research, pre-clinical and devel- apace in big pharma with the mega-mergers of
opment functions, often with conflicting priorities. Merck-Schering Plough-Organon and Pfizer-
Wyeth. Eli Lilly and GlaxoSmithKline have
announced outsourcing initiatives and Sanofi-
COUNTRY LOCATION ONE-TIME OWNER Aventis a reorganisation of its R&D. All have
internal isotope groups so we wait to see what
Fr Romainville Roussel Uclaf
impact, if any, this has on their custom radiola-
belling activities.
ITA Verono Glaxo Spa
What is certain is that the custom radiolabelling
UK Beckenham Burroughs Wellcome
companies have taken the view that outsourcing will
continue to grow and have invested to ensure they
UK Billingham Zeneca Specialities remain ahead of the curve and are ready to meet the
increased demands of their clients. DDW
UK Brockham Park Beecham
UK Dagenham Rhone-Poulenc
UK Great Burgh Beecham
UK Greenford Glaxo
UK Harlow Smith Kline Beecham
UK Horsham Ciba Geigy
UK Milton Keynes Hoechst
UK Nottingham Boots
UK Ware Glaxo
UK Welwyn Roche
UK Welwyn Smith Kline French
USA Ann Arbor, MI Parke-Davis, Warner Lambert
USA Cincinnati, OH Hoechst Marion Roussel
USA Chesterfield, MO Pharmacia
USA Kalamazoo, MI Pharmacia Upjohn
USA King of Prussia, PA Smith Kline French
USA Palo Alto, CA Roche Bioscience (Syntex)
Dave Roberts is Business Development Director
USA RTP NC Burroughs Wellcome
with Selcia Ltd. Starting as a synthetic chemist he
spent more than 20 years with Rhone-Poulenc and
USA Skokie, IL Searle
Aventis. In 2001 he was a founder of the spin-out
USA Summit, NJ Ciba Geigy
which was to become Selcia in 2005 and has been
closely involved in the expansion of their radiola-
Table 2: Pharma isotope groups closed since 1980 belling business.
60 Drug Discovery World Winter 2009/10
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88